dr. agarwal on the stampede and latitude trials for prostate cancer
Published 7 years ago • 652 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
1:27
dr. zhang discusses the impact of the stampede trial in prostate cancer
-
1:26
dr. agarwal on potential agents for metastatic hormone-sensitive prostate cancer
-
2:13
dr. agarwal on the cosmic-021 trial design in castration-resistant prostate cancer
-
1:32
dr. agarwal on treatment for newly diagnosed prostate cancer
-
1:37
dr. agarwal on drug development in metastatic castration-sensitive prostate cancer
-
1:17
dr. aggarwal on the future of adt for patients with prostate cancer
-
1:18
results of the latitude trial in high-risk metastatic hormone-naive prostate cancer
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
1:51
recent trials in advanced prostate cancer: stampede and adrad
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
1:00
dr. aggarwal on androgen deprivation therapy for prostate cancer
-
1:46
dr. agarwal on the qol with apalutamide in metastatic castration-sensitive prostate cancer
-
1:11
dr. burgess on the synergy between abiraterone and adt in prostate cancer
-
1:05
dr. agarwal on candidates for docetaxel versus abiraterone and prednisone
-
1:54
dr. agarwal on developing biomarkers of response to cabozantinib/atezolizumab in mcrpc
-
1:06
dr. agarwal on the checkmate-214 trial for kidney cancer
-
1:55
dr. garcia discusses the latitude study in prostate cancer
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
6:39
latitude supports first-line abiraterone use for metastatic prostate cancer | kim chi